tradingkey.logo

BUZZ-Barclays starts coverage on Natera with 'outperform' rating

ReutersJan 24, 2025 12:56 PM

Brokerage Barclays starts coverage on genetic testing firm Natera NTRA.O with "overweight" rating and sets PT at $200

PT represents 16.4% upside to stock's last close

Brokerage says NTRA has a "compelling long-term investment" opportunity due to its portfolio diversification in high-growth markets with significant potential for market expansion

Barclays says it is confident the company will continue to report strong results through 2025 driven by sales growth and price increases across its portfolio

NTRA more than tripled in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI